Bedaquiline Resistance and Molecular Characterization of Rifampicin-Resistant Mycobacterium Tuberculosis Isolates in Zhejiang, China

References

• World Health Organization. Global tuberculosis report 2022[EB/OL]. Available from:https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022. Accessed October 19, 2023.
   Google Scholar
• El Hamdouni M, Bourkadi JE, Benamor J, Hassar M, Cherrah Y, Ahid S. Treatment outcomes of drug resistant tuberculosis patients in Morocco: multi-centric prospective study. BMC Infect Dis. 2019;19(1):1–7. doi:10.1186/s12879-019-3931-5
   PubMedGoogle Scholar
• Getahun B, Ameni G, Medhin G, Biadgilign S. Treatment outcome of tuberculosis patients under directly observed treatment in Addis Ababa, Ethiopia. Braz J Infect Dis. 2013;17(5):521–528. doi:10.1016/j.bjid.2012.12.010
   PubMed Web of Science ®Google Scholar
• World Health Organization. World health statistics; 2021. Available from: https://www.who.int/data/gho/publications/world-health-statistics. Accessed October 19, 2023.
   Google Scholar
• Yao C, Guo H, Li Q, et al. Prevalence of extensively drug-resistant tuberculosis in a Chinese multidrug-resistant TB cohort after redefinition. Antimicrob Resist Infect Control. 2021;10(1):126. doi:10.1186/s13756-021-00995-8
   PubMed Web of Science ®Google Scholar
• Angula KT, Legoabe LJ, Beteck RM. Chemical classes presenting novel antituberculosis agents currently in different phases of drug development: a 2010–2020 review. Pharmaceuticals. 2021;14(5):461. doi:10.3390/ph14050461
   Web of Science ®Google Scholar
• Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med. 2009;360(23):2397–2405. doi:10.1056/NEJMoa0808427
   PubMed Web of Science ®Google Scholar
• Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med. 2014;371(8):723–732. doi:10.1056/NEJMoa1313865
   PubMed Web of Science ®Google Scholar
• Padhi A, Naik SK, Sengupta S, Ganguli G, Sonawane A. Expression of Mycobacterium tuberculosis NLPC/p60 family protein Rv0024 induce biofilm formation and resistance against cell wall acting anti-tuberculosis drugs in Mycobacterium smegmatis. Microbes Infect. 2016;18(4):224–236. doi:10.1016/j.micinf.2015.11.007
   PubMed Web of Science ®Google Scholar
• Diacon A, Donald P, Pym A, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother. 2012;56(6):3271–3276. doi:10.1128/AAC.06126-11
   PubMed Web of Science ®Google Scholar
• Huitric E, Verhasselt P, Koul A, Andries K, Hoffner S, Andersson DI. Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother. 2010;54(3):1022–1028. doi:10.1128/aac.01611-09
   PubMed Web of Science ®Google Scholar
• Segala E, Sougakoff W, Nevejans-Chauffour A, Jarlier V, Petrella S. New mutations in the mycobacterial ATP synthase: new insights into the binding of the diarylquinoline TMC207 to the ATP synthase C-ring structure. Antimicrob Agents Chemother. 2012;56(5):2326–2334. doi:10.1128/aac.06154-11
   PubMed Web of Science ®Google Scholar
• Zimenkov DV, Nosova EY, Kulagina EV, et al. Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region. J Antimicrob Chemother. 2017;72(7):1901–1906. doi:10.1093/jac/dkx094
   PubMed Web of Science ®Google Scholar
• Andries K, Villellas C, Coeck N, et al. Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PLoS One. 2014;9(7):e102135. doi:10.1371/journal.pone.0102135
   PubMed Web of Science ®Google Scholar
• Almeida D, Ioerger T, Tyagi S, et al. Mutations in pepQ confer low-level resistance to bedaquiline and clofazimine in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2016;60(8):4590–4599. doi:10.1128/aac.00753-16
   PubMed Web of Science ®Google Scholar
• Nieto Ramirez LM, Quintero Vargas K, Diaz G. Whole genome sequencing for the analysis of drug resistant strains of Mycobacterium tuberculosis: a systematic review for bedaquiline and delamanid. Antibiotics. 2020;9(3):133. doi:10.3390/antibiotics9030133
   Google Scholar
• Degiacomi G, Sammartino JC, Sinigiani V, Marra P, Urbani A, Pasca MR. In vitro study of bedaquiline resistance in Mycobacterium tuberculosis multi-drug resistant clinical isolates. Front Microbiol. 2020;11:559469. doi:10.3389/fmicb.2020.559469
   PubMedGoogle Scholar
• Qian W, Yu Z, Kui L, Wei W, Bin C, Songhua C. Epidemiological characteristics of pulmonary tuberculosis in Zhejiang Province from 2016 to 2020. Prev Med. 2022;34(05):487–491. doi:10.19485/j.cnki.issn2096-5087.2022.05.013
   Google Scholar
• Zhou L, Wu B, Huang F, et al. Drug resistance patterns and dynamics of tuberculosis in Zhejiang Province, China: results from five periodic longitudinal surveys. Front Public Health. 2022;10:1047659. doi:10.3389/fpubh.2022.1047659
   PubMed Web of Science ®Google Scholar
• Agnarson AM, Wang XC, Potluri R, et al. Long-term impact of the adoption of bedaquiline-containing regimens on the burden of drug-resistant tuberculosis in China. BMC Infect Dis. 2020;20(1):113. doi:10.1186/s12879-020-4795-4
   PubMed Web of Science ®Google Scholar
• Gao M, Gao J, Xie L, et al. Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study. Clin Microbiol Infect. 2021;27(4):597–602. doi:10.1016/j.cmi.2020.06.004
   PubMed Web of Science ®Google Scholar
• Zhang SJ, Yang Y, Sun WW, et al. Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China. BMC Infect Dis. 2022;22(1):715. doi:10.1186/s12879-022-07693-9
   PubMed Web of Science ®Google Scholar
• Naveen G, Peerapur BV. Comparison of the Lowenstein-Jensen Medium, the Middlebrook 7H10 Medium and MB/BacT for the Isolation of Mycobacterium Tuberculosis (MTB) from Clinical Specimens. J Clin Diagn Res. 2012;6(10):1704–1709. doi:10.7860/JCDR/2012/4603.2635
   PubMedGoogle Scholar
• Lewis I, James S Performance standards for antimicrobial susceptibility testing. 2022.
   Google Scholar
• World Health Organization. Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. World Health Organization; 2014.
   Google Scholar
• He W, Liu C, Liu D, et al. Prevalence of Mycobacterium tuberculosis resistant to bedaquiline and delamanid in China. J Glob Antimicrob Resist. 2021;26:241–248. doi:10.1016/j.jgar.2021.06.007
   PubMed Web of Science ®Google Scholar
• Kaniga K, Aono A, Borroni E, et al. Validation of bedaquiline phenotypic drug susceptibility testing methods and breakpoints: a multilaboratory, multicountry study. J Clin Microbiol. 2020;58(4). doi:10.1128/jcm.01677-19
   PubMed Web of Science ®Google Scholar
• Kigozi E, Kasule GW, Musisi K, et al. Prevalence and patterns of rifampicin and isoniazid resistance conferring mutations in Mycobacterium tuberculosis isolates from Uganda. PLoS One. 2018;13(5):e0198091. doi:10.1371/journal.pone.0198091
   PubMed Web of Science ®Google Scholar
• Wood DE, Salzberg SL. Kraken: ultrafast metagenomic sequence classification using exact alignments. Genome Biol. 2014;15(3):R46. doi:10.1186/gb-2014-15-3-r46
   PubMed Web of Science ®Google Scholar
• Freschi L, Vargas JR, Husain A, et al. Population structure, biogeography and transmissibility of Mycobacterium tuberculosis. Nat Commun. 2021;12(1):6099. doi:10.1038/s41467-021-26248-1
   PubMed Web of Science ®Google Scholar
• Coll F, McNerney R, Preston MD, et al. Rapid determination of anti-tuberculosis drug resistance from whole-genome sequences. Genome Med. 2015;7(1):51. doi:10.1186/s13073-015-0164-0
   PubMed Web of Science ®Google Scholar
• Ahmad N, Ahuja SD, Akkerman OW, et al. Collaborative Group for the Meta-Analysis of Individual Patient Data in MDRTBt. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet. 2018;392(10150):821–834. doi:10.1016/S0140-6736(18)31644-1
   PubMed Web of Science ®Google Scholar
• Khoshnood S, Goudarzi M, Taki E, et al. Bedaquiline: current status and future perspectives. J Glob Antimicrob Resist. 2021;25:48–59. doi:10.1016/j.jgar.2021.02.017
   PubMed Web of Science ®Google Scholar
• Veziris N, Bernard C, Guglielmetti L, et al. Rapid emergence of Mycobacterium tuberculosis bedaquiline resistance: lessons to avoid repeating past errors. Eur Respir J. 2017;49(3):1601719. doi:10.1183/13993003.01719-2016
   PubMed Web of Science ®Google Scholar
• Peretokina IV, Krylova LY, Antonova OV, et al. Reduced susceptibility and resistance to bedaquiline in clinical M. tuberculosis isolates. J Infect. 2020;80(5):527–535. doi:10.1016/j.jinf.2020.01.007
   PubMed Web of Science ®Google Scholar
• Pang Y, Zong Z, Huo F, et al. In vitro drug susceptibility of bedaquiline, delamanid, linezolid, clofazimine, moxifloxacin, and gatifloxacin against extensively drug-resistant tuberculosis in Beijing, China. Antimicrob Agents Chemother. 2017;61(10):128. doi:10.1128/AAC.00900-17
   Web of Science ®Google Scholar
• Liu Y, Gao M, Du J, et al. Reduced susceptibility of mycobacterium tuberculosis to bedaquiline during antituberculosis treatment and its correlation with clinical outcomes in China. Clin Infect Dis. 2021;73(9):e3391–e7. doi:10.1093/cid/ciaa1002
   PubMed Web of Science ®Google Scholar
• Yang J, Pang Y, Zhang T, et al. Molecular characteristics and in vitro susceptibility to bedaquiline of Mycobacterium tuberculosis isolates circulating in Shaanxi, China. Int J Infect Dis. 2020;99:163–170. doi:10.1016/j.ijid.2020.07.044
   PubMed Web of Science ®Google Scholar
• Pym AS, Diacon AH, Tang S-J, et al. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. Eur Respir J. 2016;47(2):564–574. doi:10.1183/13993003.00724-2015
   PubMed Web of Science ®Google Scholar
• Villellas C, Coeck N, Meehan CJ, et al. Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline. J Antimicrob Chemother. 2017;72(3):684–690. doi:10.1093/jac/dkw502
   PubMed Web of Science ®Google Scholar
• Zhao Y, Xu S, Wang L, et al. National survey of drug-resistant tuberculosis in China. N Engl J Med. 2012;366(23):2161–2170. doi:10.1056/NEJMoa1108789
   PubMed Web of Science ®Google Scholar
• Dookie N, Rambaran S, Padayatchi N, Mahomed S, Naidoo K. Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants of resistance and implications for personalized care. J Antimicrob Chemother. 2018;73(5):1138–1151. doi:10.1093/jac/dkx506
   PubMed Web of Science ®Google Scholar
• El Mahalli AA, Al-Qahtani MF. Predictors of drug resistance in tuberculosis patients in the Eastern Province, Saudi Arabia. J Egypt Public Health Assoc. 2015;90(1):24–28. doi:10.1097/01.EPX.0000461677.83722.78
   PubMedGoogle Scholar
• Jacobs MG, Pelissari DM, Pinto VL. Factors associated with the drug-resistant tuberculosis incidence rate in Brazil. Int J Tuberc Lung Dis. 2018;22(6):675–680. doi:10.5588/ijtld.17.0667
   PubMed Web of Science ®Google Scholar
• Faustini A, Hall AJ, Perucci CA. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax. 2006;61(2):158–163. doi:10.1136/thx.2005.045963
   PubMed Web of Science ®Google Scholar
• Nava-Aguilera E, Andersson N, Harris E, et al. Risk factors associated with recent transmission of tuberculosis: systematic review and meta-analysis. Int J Tuberc Lung Dis. 2009;13(1):17–26.
   PubMed Web of Science ®Google Scholar
• Baluku JB, Mukasa D, Bongomin F, et al. Gender differences among patients with drug resistant tuberculosis and HIV co-infection in Uganda: a countrywide retrospective cohort study. BMC Infect Dis. 2021;21(1):1093. doi:10.1186/s12879-021-06801-5
   PubMed Web of Science ®Google Scholar
• Jou R, Chuang PC, Wu YS, Yan JJ, Luh KT. Drug-resistant Mycobacterium tuberculosis, Taiwan. Emerg Infect Dis. 2006;12(5):871–872. doi:10.3201/eid1205.051688
   PubMed Web of Science ®Google Scholar
• Liu Z, Dong H, Wu B, et al. Is rifampin resistance a reliable predictive marker of multidrug-resistant tuberculosis in China: a meta-analysis of findings. J Infect. 2019;79(4):349–356. doi:10.1016/j.jinf.2019.08.004
   PubMed Web of Science ®Google Scholar
• Xiuli S, Mingxia J, Zhaofen W, et al. Current situation of drug resistance of 236 mycobacterium tuberculosis from Qinghai. Chin J Dis Cont Prev. 2017;21(04):353–356. doi:10.16462/j.cnki.zhjbkz.2017.04.008
   Google Scholar
• Omar SV, Ismail F, Ndjeka N, Kaniga K, Ismail NA. Bedaquiline-Resistant Tuberculosis Associated with Rv0678 Mutations. N Engl J Med. 2022;386(1):93–94. doi:10.1056/NEJMc2103049
   PubMed Web of Science ®Google Scholar
• Kabahita JM, Kabugo J, Kakooza F, et al. First report of whole-genome analysis of an extensively drug-resistant Mycobacterium tuberculosis clinical isolate with bedaquiline, linezolid and clofazimine resistance from Uganda. Antimicrob Resist Infect Control. 2022;11(1):68. doi:10.1186/s13756-022-01101-2
   PubMed Web of Science ®Google Scholar
• Guo Q, Bi J, Lin Q, et al. Whole genome sequencing identifies novel mutations associated with bedaquiline resistance in Mycobacterium tuberculosis. Front Cell Infect Microbiol. 2022;12:807095. doi:10.3389/fcimb.2022.807095
   PubMedGoogle Scholar
• Gao Q, Kripke KE, Saldanha AJ, Yan W, Holmes S, Small PM. Gene expression diversity among Mycobacterium tuberculosis clinical isolates. Microbiology. 2005;151(1):5–14. doi:10.1099/mic.0.27539-0
   PubMedGoogle Scholar
• Mudliar SKR, Kulsum U, Rufai SB, Umpo M, Nyori M, Singh S. Snapshot of Mycobacterium tuberculosis phylogenetics from an Indian State of Arunachal Pradesh Bordering China. Genes. 2022;13(2):263. doi:10.3390/genes13020263
   PubMed Web of Science ®Google Scholar
• Karmakar M, Trauer JM, Ascher DB, Denholm JT. Hyper transmission of Beijing lineage Mycobacterium tuberculosis: systematic review and meta-analysis. J Infect. 2019;79(6):572–581. doi:10.1016/j.jinf.2019.09.016
   PubMed Web of Science ®Google Scholar
• van Soolingen D, Qian L, de Haas PE, et al. Predominance of a single genotype of Mycobacterium tuberculosis in countries of east Asia. J Clin Microbiol. 1995;33(12):3234–3238. doi:10.1128/jcm.33.12.3234-3238.1995
   PubMed Web of Science ®Google Scholar
• Ramazanzadeh R, Sayhemiri K. Prevalence of Beijing family in Mycobacterium tuberculosis in world population: systematic review and meta-analysis. Int J Mycobacteriol. 2014;3(1):41–45. doi:10.1016/j.ijmyco.2014.01.001
   PubMedGoogle Scholar